Oral Delivery of Liposomes
Wei Wu,Yi Lu,Jianping Qi
DOI: https://doi.org/10.4155/tde.15.69
2015-01-01
Therapeutic Delivery
Abstract:Therapeutic DeliveryVol. 6, No. 11 EditorialFree AccessOral delivery of liposomesWei Wu, Yi Lu & Jianping QiWei Wu*Author for correspondence: E-mail Address: wuwei@shmu.edu.cn School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai 201203, ChinaSearch for more papers by this author, Yi Lu School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai 201203, ChinaSearch for more papers by this author & Jianping Qi School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai 201203, ChinaSearch for more papers by this authorPublished Online:19 Nov 2015https://doi.org/10.4155/tde.15.69AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit Keywords: absorptionactive targetingbioavailabilitydrug deliveryliposomesoralpolymeric coatingstabilityEver since the invention by Bangham in 1966, liposomes has been evolving steadily not only as a nice tool to study the function of cell membranes but also as unique drug carriers with enhanced efficacy and reduced toxicity [1,2]. Currently, liposomes present as one of the best drug delivery systems, solely owing to their capacity to encapsulate various drug entities, excellent biocompatibility and easy interaction with biomembranes. Several decades of ordeal finally gave birth to the milestone product, long-circulating doxorubicin liposomes with the brand name Doxil®, together with several other liposomal products such as amphotericin B liposomes and paclitaxel liposomes. Although originally designed for parenteral delivery, liposomes were also attempted in oral delivery as early as in the 1970s for those entities with extremely low oral bioavailability, for example, insulin. Despite of the initial excitement in the observation of enhanced bioavailability of insulin, the interests in oral liposomes subsided due to the far-lower-than-appealing bioavailability, difficulties in formulation and uncertainties in in vivo fate. However, recently saw a resurgence of oral delivery of liposomes.Challenges in oral liposome deliveryIt is an odyssey from the ingestion of liposomes to the absorption of active ingredients embedded in liposomes. The first challenge emerges when liposomes are ingested and exposed to the harsh environment of the gastrointestinal (GI) tract. Conventional liposomes that composed of phospholipids and cholesterol are found to be highly susceptible to physiological factors such as gastric acid, bile salts and lipases [3], whose destructive effects commonly result in losing of the liposomal integrity and thus leakage of the payload. Bile salts, surfactant secreted by liver, can disrupt the liposomal structure, whereas lipases are able to hydrolyze phospholipids and thereby bring about disruption of liposomes. It was observed that liposomes would lose integrity within 2 h in simulated intestinal fluid with significantly deformed structure [4].If liposomes are made survive the harsh GI environment, there follows the second challenge of poor permeability of liposomes across GI epithelia which presents as the main absorption barrier. Currently we know little about the exact mechanisms governing oral absorption of liposomes. There remains controversy over whether the active ingredients are released firsthand before being absorbed or whether the liposomes together with their payload can be absorbed intact by the GI epithelia. The mucus lining that coats and protects the GI epithelia sheds frequently, which as a result clears the substances that cannot penetrate the mucous layer quickly enough [5]. Albeit there is chance for liposomes to penetrate the mucous layer, the GI epithelia blocks the entrance of intact liposomes into the circulation because they are commonly very large in size in comparison with easily absorbable small molecules, and the GI physiology has evolved to exclude exogenous particles. Although uptake by M cells located at the surface of follicle-associated epithelium was proposed as a possible mechanism for the internalization of intact liposomes, the limited population and variation in distribution significantly restricts its value as an absorption pathway. Till now, there is no persuasive evidence on the uptake of intact liposomes by the GI epithelia.There is also a less noticeable yet important challenge during the development of liposomal formulations − the mass manufacturing challenge. Liposomes are soft self-assembled vesicles that endowed with instability during either formulation processing or storage. In spite of the successful marketing of doxorubicin liposomes product, there is not without problems in the manufacturing of liposomal formulations especially when scaling up. The batch size is still very small, which nevertheless sure will fail to meet the batch size requirement for oral administration. In order to ensure sufficient stability, solidification of the liposomes by various drying methods like freeze-drying and spray-drying has been attempted, but with little success because of the difficulties in reconstituting dried ‘liposomes’ into their original forms.Modify to improve the stability & absorption of oral liposomesIn the past decade, there is an emerging trend in the field of enhancing oral delivery of liposomes by modification of either the liposomal surfaces or the liposomal compositions. The modifications aim to enhance both the stability and the absorption of the liposomes. In addition, enhancement in stability either in vitro or in vivo results in more liposomes surviving the harsh GI environment, and thereby further adds to enhancement in oral absorption of liposomes. Although the underlying mechanisms of oral absorption of liposomes are still unclear, some strategies are tested to be highly effective to enhance either the stability or oral permeation of liposomes.By optimization of the lipid compositions, liposomes can be made more stable. It was reported that substituting common lipids with hydrogenated phospholipid of higher phase transition temperatures significantly strengthens the lipid bilayers, which serves as the basis for the Doxil® formulation. Paradoxically, incorporation of bile salts in the lipid bilayers was found to be able to stabilize the liposomes and protect the payload, rather than destabilize it [6]. Another even more effective approach to stabilizing liposomes is coating with various polymers. The coating with long-chain polyethylene glycols, similar approach employed by injectable long-circulating liposomes, was found to be able to help liposomes withstand the erosive effect of bile salts and protect the payload [7]. Other reported coating materials include chitosan, polysaccharides, proteins and their derivatives [8,9].Although the mechanisms governing oral absorption of liposomes are still not elucidated yet, various strategies were proved to be effective, for example, incorporation of enhancers, improvement of mucoadhesiveness, polymer coating and ligand-mediated targeting to epithelia [10–15]. It should be noted that some efficacy should be ascribed to enhanced stability rather than improvement in transmembrane absorption. Yet there are some approaches that do function to facilitate absorption of liposomes. For instance, besides improved stability bile salts-enriched liposomes (bilosomes) showed significantly enhanced oral bioavailability for a series of active ingredients and elicited significant immunological responses for orally vaccines [16]. Coating with polymers such as polysaccharides and chitosan reinforces the adhesion with the epithelial mucus lining and increases the opportunities of absorption of the payloads. Evidence also showed that coating with chitosan could interfere with the tight junctions and facilitate absorption of the drug, and even the liposomes as a whole. Modification with tocopheryl polyethylene glycol 1000 succinate (TPGS) and pluronics could enhance absorption through well-accepted mechanisms of inhibition of pumping out by P-glycoproteins. However, it is paradoxical that the coating will camouflage the liposomes and thereby presents the behavior of the particles of the coating materials, whereas the efficacy always depends on the recognition of naked liposomes per se. It seems that shedding mechanisms should be taken into account when designing polymer-coated liposomal delivery systems. Active targeting to the intestinal epithelia by modification with ligands is an emerging trend to increase the oral uptake of nanoparticles [16]. A majority of studies in this field employ the M cell pathway through receptor-induced phagocytosis, taking advantage of the expression of a variety of receptors on the surface of M-cells, for example, intercellular adhesion molecule-1, l-fucose and β1-integrin [17]. Lectins, a class of glycoproteins of botanical origin that can reversibly bind to specific carbohydrate residues of the surface proteins or lipids, has been observed to be able to enhance the oral absorption of liposome-bound entities [18]. However, owing to the limited population of M cells along the whole intestinal wall lining, the potential of transenterocytic phagocytic pathway has also been explored, although it is just at its beginning, aiming at various receptors for nutrients such as vitamins and carbohydrate, and proteins and peptides [19,20].Conclusion & future perspectiveIn conclusion, oral delivery of liposomes sheds light on enhanced absorption of entities of extremely low bioavailability, but only with limited progress due to the various challenges as described in this article. In general, if liposomes are intended to deliver poorly water-soluble small molecular drugs, a pathway of transition into mixed micelles before absorption by passive diffusion may be functional. However, for labile entities such as biomacromolecules, it is of utmost importance to maintain the liposomal integrity in the intestinal lumen and achieve significant uptake of the liposomes by the GI epithelia. Although there is speculation that liposomes may be absorbed intact, no direct evidence has ever been reported. To pave the way for efficient oral absorption of liposomes, leading strategies should be to stabilize liposomes both in vitro and in vivo, and enhance the uptake efficiency of liposomes by intestinal epithelia. To battle the latter, it is urgent to decipher the underlying mechanisms of oral absorption of liposomes, and thereby stimulate innovative designing of novel liposomal delivery systems with improved bioavailability.Financial & competing interests disclosureW Wu would like to thank Shanghai Commission of Science and Technology for financial support (14JC1490300). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.References1 Fan Y, Zhang Q. Development of liposomal formulations: from concept to clinical investigations. Asian J. Pharm. Sci. 8(2), 81–87 (2013).Crossref, CAS, Google Scholar2 Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4(2), 145–160 (2005).Crossref, Medline, CAS, Google Scholar3 Rowland RN, Woodley JF. The stability of liposomes in vitro to pH, bile salts and pancreatic lipase. Biochim. Biophys. Acta 620(3), 400–409 (1980).Crossref, Medline, CAS, Google Scholar4 Liu W, Ye A, Liu W et al. Behaviour of liposomes loaded with bovine serum albumin during in vitro digestion. Food Chem. 175, 16–24 (2015).Crossref, Medline, CAS, Google Scholar5 Ensign LM, Cone R, Hanes J. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv. Drug Deliv. Rev. 64(6), 557–570 (2012).Crossref, Medline, CAS, Google Scholar6 Hu S, Niu M, Hu F et al. Integrity and stability of oral liposomes containing bile salts studied in simulated and ex vivo gastrointestinal media. Int. J. Pharm. 441(1–2), 693–700 (2013).Crossref, Medline, CAS, Google Scholar7 Li H, Song JH, Park JS et al. Polyethylene glycol-coated liposomes for oral delivery of recombinant human epidermal growth factor. Int. J. Pharm. 258(1–2), 11–19 (2003).Crossref, Medline, CAS, Google Scholar8 Manconi M, Nacher A, Merino V et al. Improving oral bioavailability and pharmacokinetics of liposomal metformin by glycerolphosphate-chitosan microcomplexation. AAPS PharmSciTech 14(2), 485–496 (2013).Crossref, Medline, CAS, Google Scholar9 Smistad G, Bøyum S, Alund SJ et al. The potential of pectin as a stabilizer for liposomal drug delivery systems. Carbohydr. Polym. 90(3), 1337–1344 (2012).Crossref, Medline, CAS, Google Scholar10 Klemetsrud T, Jonassen H, Hiorth M et al. Studies on pectin-coated liposomes and their interaction with mucin. Colloids Surf. B Biointerfaces 103, 158–165 (2013).Crossref, Medline, CAS, Google Scholar11 Sugihara H, Yamamoto H, Kawashima Y et al. Effectiveness of submicronized chitosan-coated liposomes in oral absorption of indomethacin. J. Liposome Res. 22(1), 72–79 (2012).Crossref, Medline, CAS, Google Scholar12 Parmentier J, Hofhaus G, Thomas S et al. Improved oral bioavailability of human growth hormone by a combination of liposomes containing bio-enhancers and tetraether lipids and omeprazole. J. Pharm. Sci. 103(12), 3985–3993 (2014).Crossref, Medline, CAS, Google Scholar13 Huang YB, Tsai MJ, Wu PC et al. Elastic liposomes as carriers for oral delivery and the brain distribution of (+)-catechin. J. Drug Target 19(8), 709–718 (2011).Crossref, Medline, CAS, Google Scholar14 Gradauer K, Barthelmes J, Vonach C et al. Liposomes coated with thiolated chitosan enhance oral peptide delivery to rats. J. Control. Release 172(3), 872–878 (2013).Crossref, Medline, CAS, Google Scholar15 Chen D, Xia D, Li X et al. Comparative study of Pluronic® F127-modified liposomes and chitosan-modified liposomes for mucus penetration and oral absorption of cyclosporine A in rats. Int. J. Pharm. 449(1–2), 1–9 (2013).Crossref, Medline, CAS, Google Scholar16 Zhang X, Wu W. Ligand-mediated active targeting for enhanced oral absorption. Drug Discov. Today 19(7), 898–904 (2014).Crossref, Medline, CAS, Google Scholar17 des Rieux A, Pourcelle V, Cani PD et al. Targeted nanoparticles with novel non-peptidic ligands for oral delivery. Adv. Drug Deliv. Rev. 65(6), 833–844 (2013).Crossref, Medline, CAS, Google Scholar18 Makhlof A, Fujimoto S, Tozuka Y et al. In vitro and in vivo evaluation of WGA-carbopol modified liposomes as carriers for oral peptide delivery. Eur. J. Pharm. Biopharm. 77(2), 216–224 (2011).Crossref, Medline, CAS, Google Scholar19 Zhang X, Qi J, Lu Y et al. Biotinylated liposomes as potential carriers for the oral delivery of insulin. Nanomedicine 10(1), 167–176 (2014).Crossref, Medline, CAS, Google Scholar20 Agrawal AK, Harde H, Thanki K et al. Improved stability and antidiabetic potential of insulin containing folic acid functionalized polymer stabilized multilayered liposomes following oral administration. Biomacromolecules 15(1), 350–360 (2014).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByHydrogel-based formulations for drug delivery to the anterior segment of the eyeJournal of Drug Delivery Science and Technology, Vol. 81Novel Approach for the Approximation of Vitamin D3 Pharmacokinetics from In Vivo Absorption Studies27 February 2023 | Pharmaceutics, Vol. 15, No. 3Coating Materials to Increase the Stability of Liposomes3 February 2023 | Polymers, Vol. 15, No. 3Stability and release of bioactives from liposomesSelenized liposomes with ameliorative stability that achieve sustained release of emodin but fail in bioavailabilityChinese Chemical Letters, Vol. 34, No. 1Corneal sustained delivery of hyaluronic acid from nanofiber-containing ring-implanted contact lens23 December 2022 | Journal of Biomaterials Applications, Vol. 94Efficient oral delivery of water-soluble CT contrast agent using an W1/O/W2 alginate hydrogel matrixColloids and Surfaces B: Biointerfaces, Vol. 220Liposomes as biocompatible and smart delivery systems – the current stateAdvances in Colloid and Interface Science, Vol. 309Targeted co-delivery of daunorubicin and cytarabine based on the hyaluronic acid prodrug modified liposomesChinese Chemical Letters, Vol. 33, No. 10Vortioxetine liposomes as a novel alternative to improve drug stability under stress conditions: toxicity studies and evaluation of antidepressant-like effect9 September 2022 | Pharmacological Reports, Vol. 74, No. 5Tailoring the multi-functional properties of phospholipids for simple to complex self-assembliesJournal of Controlled Release, Vol. 349Exploring the impact of physicochemical properties of liposomal formulations on their in vivo fateLife Sciences, Vol. 300Liposomal-Based Formulations: A Path from Basic Research to Temozolomide Delivery Inside Glioblastoma Tissue27 January 2022 | Pharmaceutics, Vol. 14, No. 2Nanovesicles-Mediated Drug Delivery for Oral Bioavailability Enhancement1 October 2022 | International Journal of Nanomedicine, Vol. Volume 17Effect of pluronic block composition on the structure, stability, and cytotoxicity of liposomes12 June 2020 | Journal of Dispersion Science and Technology, Vol. 42, No. 11Trends in liposomal nanocarrier strategies for the oral delivery of biologicsNanomedicine, Vol. 16, No. 20Preparation of Nanoparticle‐Containing Ring‐Implanted Poly(Vinyl Alcohol) Contact Lens for Sustained Release of Hyaluronic Acid20 May 2021 | Macromolecular Bioscience, Vol. 21, No. 7Characterization and Caco-2 Cell Transport Assay of Chito-Oligosaccharides Nano-Liposomes Based on Layer-by-Layer Coated7 July 2021 | Molecules, Vol. 26, No. 14Liposomes for oral delivery of protein and peptide-based therapeutics: challenges, formulation strategies, and advances1 January 2021 | Journal of Materials Chemistry B, Vol. 9, No. 24Design and evaluation of mucoadhesive in situ liposomal gel for sustained ocular delivery of travoprost using two steps factorial designJournal of Drug Delivery Science and Technology, Vol. 61Self-Assembling Lipid Nanoparticles/Nanosystems (SLNN) Using Hydrophilic Solvents: Overview and Industrial Uses24 June 2021Ternary nanocomposite carriers based on organic clay-lipid vesicles as an effective colon-targeted drug delivery system: preparation and in vitro/in vivo characterization21 January 2020 | Journal of Nanobiotechnology, Vol. 18, No. 1Bile acid transporter-mediated oral drug deliveryJournal of Controlled Release, Vol. 327Recent Advances in Liposomal Drug Delivery System of Quercetin for Cancer Targeting: A Mechanistic ApproachCurrent Drug Delivery, Vol. 17, No. 10Molecular Design of Layer-by-Layer Functionalized Liposomes for Oral Drug Delivery2 September 2020 | ACS Applied Materials & Interfaces, Vol. 12, No. 39Spontaneous In Situ Formation of Liposomes from Inert Porous Microparticles for Oral Drug Delivery15 August 2020 | Pharmaceutics, Vol. 12, No. 8Oral delivery of natural compounds by phospholipid vesiclesNanomedicine, Vol. 15, No. 18Review of recently used techniques and materials to improve the efficiency of orally administered proteins/peptides6 December 2019 | DARU Journal of Pharmaceutical Sciences, Vol. 28, No. 1Molecular targeting of FATP4 transporter for oral delivery of therapeutic peptideScience Advances, Vol. 6, No. 14Recent Advances in Inhaled Formulations and Pulmonary Insulin Delivery SystemsCurrent Pharmaceutical Biotechnology, Vol. 21, No. 3Liposomes for Enhanced Bioavailability of Water-Insoluble Drugs: In Vivo Evidence and Recent Approaches13 March 2020 | Pharmaceutics, Vol. 12, No. 3Recent advancements in liposome technologyAdvanced Drug Delivery Reviews, Vol. 156Bioinspired Liposomes for Oral Delivery of Colistin to Combat Intracellular Infections by Salmonella enterica22 July 2019 | Advanced Healthcare Materials, Vol. 8, No. 17Internalization and subcellular transport mechanisms of different curcumin loaded nanocarriers across Caco-2 cell modelJournal of Drug Delivery Science and Technology, Vol. 52Anionic versus cationic bilosomes as oral nanocarriers for enhanced delivery of the hydrophilic drug risedronateInternational Journal of Pharmaceutics, Vol. 564Adapting liposomes for oral drug deliveryActa Pharmaceutica Sinica B, Vol. 9, No. 1Active Targeting of Drugs and Bioactive Molecules via Oral Administration by Ligand-Conjugated Lipidic Nanocarriers: Recent Advances18 December 2018 | AAPS PharmSciTech, Vol. 20, No. 1Curcumin alleviates postprandial glycaemic response in healthy subjects: A cross-over, randomized controlled study12 September 2018 | Scientific Reports, Vol. 8, No. 1Enhanced oral absorption of sorafenib via the layer-by-layer deposition of a pH-sensitive polymer and glycol chitosan on the liposomeInternational Journal of Pharmaceutics, Vol. 544, No. 1Exploiting or overcoming the dome trap for enhanced oral immunization and drug deliveryJournal of Controlled Release, Vol. 275Improved hepatoprotective activity of silymarin via encapsulation in the novel vesicular nanosystem bilosomes13 August 2017 | Drug Development and Industrial Pharmacy, Vol. 43, No. 12Chitosan-modified cholesterol-free liposomes for improving the oral bioavailability of progesteroneColloids and Surfaces B: Biointerfaces, Vol. 159Development of Liposome containing sodium deoxycholate to enhance oral bioavailability of itraconazoleAsian Journal of Pharmaceutical Sciences, Vol. 12, No. 2Preparation, characterization and in vivo pharmacokinetic study of PVP-modified oleanolic acid liposomesInternational Journal of Pharmaceutics, Vol. 517, No. 1-2Ethylcellulose oleogels for lipophilic bioactive delivery – effect of oleogelation on in vitro bioaccessibility and stability of beta-carotene1 January 2017 | Food & Function, Vol. 8, No. 4Evaluation of mesoporous silica nanoparticles for oral drug delivery – current status and perspective of MSNs drug carriers1 January 2017 | Nanoscale, Vol. 9, No. 40A Mechanistic Study on Nanoparticle-Mediated Glucagon-Like Peptide-1 (GLP-1) Secretion from Enteroendocrine L Cells18 November 2016 | Molecular Pharmaceutics, Vol. 13, No. 12Reformulating cyclosporine A (CsA): More than just a life cycle management strategyJournal of Controlled Release, Vol. 225 Vol. 6, No. 11 Follow us on social media for the latest updates Metrics History Published online 19 November 2015 Published in print November 2015 Information© Future Science LtdKeywordsabsorptionactive targetingbioavailabilitydrug deliveryliposomesoralpolymeric coatingstabilityFinancial & competing interests disclosureW Wu would like to thank Shanghai Commission of Science and Technology for financial support (14JC1490300). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download